• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新诊断特发性肺纤维化日本患者用力肺活量的 6 个月连续变化可预测随后的下降和死亡率。

Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.

机构信息

Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.

Department of Laboratory of Pathology, Nagasaki University Hospital, Nagasaki, Japan.

出版信息

Respir Investig. 2021 May;59(3):335-341. doi: 10.1016/j.resinv.2020.12.008. Epub 2021 Feb 4.

DOI:10.1016/j.resinv.2020.12.008
PMID:33551330
Abstract

BACKGROUND

The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function; however, predicting changes in lung function is difficult. We sought to determine whether the prior 6-month trend in forced vital capacity (FVC) could predict mortality and the subsequent 6-month trend in FVC.

METHODS

We retrospectively analyzed consecutive patients with newly diagnosed IPF who underwent serial pulmonary function tests. The immediate two years after the initial evaluation were divided into four terms of six months each and stratified on the basis of presence or absence of a ≥10% relative decline in FVC at six months (declined and stable groups, respectively).

RESULTS

We included 107 patients with %predicted FVC of 80.8% and %predicted diffusing capacity of the lung for carbon monoxide of 58.9%. In multivariate analysis, a decline in %predicted FVC in the initial six months was found to be an independent prognostic factor (hazard ratio 4.45, 95% confidence interval 2.62-7.56, p < 0.01). Among the 46 terms in which the FVC declined during the initial 1.5-year study period, a decline in FVC was exhibited in 23 (50.0%) of the subsequent terms. Among 231 terms in which FVC remained stable, a decline was observed in 32 (13.9%) of the subsequent terms (relative risk 3.61, p < 0.01). The frequency of FVC decline in each term was 16-27%. FVC was stable or declined in all four terms in 50.5% and 15.9% of cases, respectively.

CONCLUSIONS

Six-month decline in FVC predicts subsequent FVC change and mortality in IPF patients in the era of antifibrotic agents.

摘要

背景

特发性肺纤维化(IPF)的临床病程表现为肺功能逐渐下降;然而,预测肺功能变化具有一定难度。我们旨在确定 FVC(用力肺活量)在过去 6 个月的变化趋势是否可以预测死亡率和随后 6 个月的 FVC 变化趋势。

方法

我们回顾性分析了连续诊断为 IPF 并接受了系列肺功能检测的患者。初始评估后的两年内,每 6 个月分为 4 个时间段,并根据 FVC 在 6 个月时是否下降≥10%(分别为下降组和稳定组)进行分层。

结果

我们纳入了 107 名 FVC%预计值为 80.8%和一氧化碳弥散量%预计值为 58.9%的患者。多变量分析显示,最初 6 个月 FVC%预计值下降是独立的预后因素(危险比 4.45,95%置信区间 2.62-7.56,p<0.01)。在最初 1.5 年的研究期间,46 个时间段中有 46 个 FVC 下降,其中 23 个(50.0%)随后的时间段中 FVC 仍持续下降。在 231 个 FVC 稳定的时间段中,有 32 个(13.9%)随后的时间段中 FVC 下降(相对风险 3.61,p<0.01)。每个时间段 FVC 下降的频率为 16-27%。在所有四个时间段中,50.5%的患者 FVC 稳定或下降,15.9%的患者 FVC 持续下降。

结论

在抗纤维化药物时代,FVC 在过去 6 个月的下降预示着 IPF 患者随后的 FVC 变化和死亡率。

相似文献

1
Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis.新诊断特发性肺纤维化日本患者用力肺活量的 6 个月连续变化可预测随后的下降和死亡率。
Respir Investig. 2021 May;59(3):335-341. doi: 10.1016/j.resinv.2020.12.008. Epub 2021 Feb 4.
2
Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.特发性肺纤维化患者在接受抗纤维化治疗前后用力肺活量下降的预后意义。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620953783. doi: 10.1177/1753466620953783.
3
Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.新诊断的特发性肺纤维化患者用力肺活量的变化及相关后续结局
BMC Pulm Med. 2015 Dec 29;15:167. doi: 10.1186/s12890-015-0161-5.
4
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.特发性肺纤维化患者用力肺活量急性加重和下降与死亡率升高相关。
Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
5
Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.特发性肺纤维化患者六分钟步行试验的临床意义:一项回顾性队列研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241275329. doi: 10.1177/17534666241275329.
6
Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.用力肺活量呈边际下降与特发性肺纤维化的不良预后相关。
Eur Respir J. 2010 Apr;35(4):830-6. doi: 10.1183/09031936.00155108. Epub 2009 Oct 19.
7
Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.经手术证实为普通型间质性肺炎的特发性肺纤维化新定义急性加重:危险因素与预后
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(1):39-46. doi: 10.36141/svdld.v36i1.7117. Epub 2019 May 1.
8
Prognostic implication of 1-year decline in diffusing capacity in newly diagnosed idiopathic pulmonary fibrosis.新诊断特发性肺纤维化中弥散量 1 年下降的预后意义。
Sci Rep. 2024 Apr 17;14(1):8857. doi: 10.1038/s41598-024-59649-5.
9
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验:吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
10
Predicting pulmonary fibrosis disease course from past trends in pulmonary function.从过去的肺功能趋势预测肺纤维化疾病进程。
Chest. 2014 Mar 1;145(3):579-585. doi: 10.1378/chest.13-0844.